231 related articles for article (PubMed ID: 28347667)
41. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
[TBL] [Abstract][Full Text] [Related]
42. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
43. Investigation of novel ligand targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery: complete pharmacophore approach.
Shanmugam V; Muthukrishnan S
J Biomol Struct Dyn; 2023; 41(23):14524-14539. PubMed ID: 36841551
[TBL] [Abstract][Full Text] [Related]
44. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
[TBL] [Abstract][Full Text] [Related]
45. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
[TBL] [Abstract][Full Text] [Related]
46. Pyronaridine as a Bromodomain-Containing Protein 4-
Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
[TBL] [Abstract][Full Text] [Related]
47. Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
Borysko P; Moroz YS; Vasylchenko OV; Hurmach VV; Starodubtseva A; Stefanishena N; Nesteruk K; Zozulya S; Kondratov IS; Grygorenko OO
Bioorg Med Chem; 2018 Jul; 26(12):3399-3405. PubMed ID: 29764756
[TBL] [Abstract][Full Text] [Related]
48. Targeting BET bromodomains for cancer treatment.
Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
[TBL] [Abstract][Full Text] [Related]
49. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
[TBL] [Abstract][Full Text] [Related]
50. New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival.
Vilaboa N; Boré A; Martin-Saavedra F; Bayford M; Winfield N; Firth-Clark S; Kirton SB; Voellmy R
Nucleic Acids Res; 2017 Jun; 45(10):5797-5817. PubMed ID: 28369544
[TBL] [Abstract][Full Text] [Related]
51. An Overview on Small Molecule Inhibitors of BRD4.
Huang W; Zheng X; Yang Y; Wang X; Shen Z
Mini Rev Med Chem; 2016; 16(17):1403-1414. PubMed ID: 27290915
[TBL] [Abstract][Full Text] [Related]
52. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
53. Identification of small molecule inhibitors targeting the SMARCA2 bromodomain from a high-throughput screening assay.
Lu T; Hu JC; Lu WC; Han J; Ding H; Jiang H; Zhang YY; Yue LY; Chen SJ; Jiang HL; Chen KX; Chai HF; Luo C
Acta Pharmacol Sin; 2018 Sep; 39(9):1544-1552. PubMed ID: 29795359
[TBL] [Abstract][Full Text] [Related]
54. BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.
Ayoub AM; Hawk LML; Herzig RJ; Jiang J; Wisniewski AJ; Gee CT; Zhao P; Zhu JY; Berndt N; Offei-Addo NK; Scott TG; Qi J; Bradner JE; Ward TR; Schönbrunn E; Georg GI; Pomerantz WCK
J Med Chem; 2017 Jun; 60(12):4805-4817. PubMed ID: 28535045
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.
Rong J; Feng ZZ; Shi YJ; Ren J; Xu Y; Wang NY; Xue Q; Liu KL; Zhou SY; Wei W; Yu LT
Bioorg Med Chem Lett; 2019 Oct; 29(19):126577. PubMed ID: 31421967
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis and biological evaluation of 7-methylimidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD4 inhibitors.
Zhao L; Yang Y; Guo Y; Yang L; Zhang J; Zhou J; Zhang H
Bioorg Med Chem; 2017 Apr; 25(8):2482-2490. PubMed ID: 28314513
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
58. Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.
Allen BK; Mehta S; Ember SW; Schonbrunn E; Ayad N; Schürer SC
Sci Rep; 2015 Nov; 5():16924. PubMed ID: 26596901
[TBL] [Abstract][Full Text] [Related]
59. Biased multicomponent reactions to develop novel bromodomain inhibitors.
McKeown MR; Shaw DL; Fu H; Liu S; Xu X; Marineau JJ; Huang Y; Zhang X; Buckley DL; Kadam A; Zhang Z; Blacklow SC; Qi J; Zhang W; Bradner JE
J Med Chem; 2014 Nov; 57(21):9019-27. PubMed ID: 25314271
[TBL] [Abstract][Full Text] [Related]
60. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
